| Year |
Citation |
Score |
| 2024 |
Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 76: 101103. PMID 38943828 DOI: 10.1016/j.drup.2024.101103 |
0.41 |
|
| 2024 |
Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, Bucheit L, Medford AJ, Wagle N, Bardia A, Wander SA. CDK4/6 Inhibitor Efficacy in -Mutant Metastatic Breast Cancer. Nejm Evidence. 3: EVIDoa2300231. PMID 38815172 DOI: 10.1056/EVIDoa2300231 |
0.364 |
|
| 2024 |
Keenan JC, Medford AJ, Dai CS, Wander SA, Spring LM, Bardia A. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child. Expert Review of Anticancer Therapy. 1-9. PMID 38642015 DOI: 10.1080/14737140.2024.2346188 |
0.305 |
|
| 2024 |
Wander SA, Bardia A. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38319645 DOI: 10.1158/1078-0432.CCR-23-3413 |
0.313 |
|
| 2023 |
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, et al. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Research : Bcr. 25: 112. PMID 37784176 DOI: 10.1186/s13058-023-01718-0 |
0.301 |
|
| 2023 |
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, ... ... Wander SA, et al. A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532. PMID 37141550 DOI: 10.1200/PO.22.00532 |
0.339 |
|
| 2023 |
Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, et al. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. Jco Precision Oncology. 7: e2200531. PMID 37141549 DOI: 10.1200/PO.22.00531 |
0.334 |
|
| 2022 |
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Therapeutic Advances in Medical Oncology. 14: 17588359221113694. PMID 35923930 DOI: 10.1177/17588359221113694 |
0.301 |
|
| 2022 |
Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist. PMID 35917168 DOI: 10.1093/oncolo/oyac138 |
0.373 |
|
| 2021 |
Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34725098 DOI: 10.1158/1078-0432.CCR-21-2947 |
0.341 |
|
| 2021 |
Jiang X, Lu X, Gentles AJ, Zhao D, Wander SA, Zhang Y, Natkunam Y, Slingerland J, Reis IM, Rabinovich B, Abdulreda MH, Moy VT, Lossos IS. HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. Blood Advances. PMID 34543391 DOI: 10.1182/bloodadvances.2021004304 |
0.53 |
|
| 2021 |
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, et al. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network : Jnccn. 1-8. PMID 33761455 DOI: 10.6004/jnccn.2020.7662 |
0.35 |
|
| 2020 |
Mao P, Cohen O, Kowalski KJ, Kusiel J, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung JH, Freeman SS, Rozenblatt-Rosen O, Miller VA, Piccioni F, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32723837 DOI: 10.1158/1078-0432.Ccr-19-3958 |
0.399 |
|
| 2020 |
Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, ... Wander SA, et al. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32571788 DOI: 10.1158/1078-0432.Ccr-20-0638 |
0.385 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390 |
0.47 |
|
| 2020 |
Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32245699 DOI: 10.1016/J.Annonc.2020.02.008 |
0.421 |
|
| 2020 |
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet (London, England). 395: 817-827. PMID 32145796 DOI: 10.1016/S0140-6736(20)30165-3 |
0.464 |
|
| 2020 |
Spring L, Griffin C, Isakoff SJ, Moy B, Wander SA, Shin J, Abraham E, Habin K, Patel JM, Comander AH, Mulvey TM, Bardia A. Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). Journal of Clinical Oncology. 38: 531-531. DOI: 10.1200/Jco.2020.38.15_Suppl.531 |
0.399 |
|
| 2020 |
Wander SA, Juric D, Supko JG, Micalizzi DS, Spring L, Vidula N, Beeler M, Habin KR, Viscosi E, Fitzgerald DM, Scarpetti L, Tripp E, Hepp R, Moy B, Isakoff SJ, et al. Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC). Journal of Clinical Oncology. 38: 1066-1066. DOI: 10.1200/Jco.2020.38.15_Suppl.1066 |
0.361 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09 |
0.483 |
|
| 2020 |
Wander S, Mao P, Lloyd M, Kowalski K, Johnson GN, Malvarosa G, Moy B, Ellisen LW, Iafrate J, Wagle N, Bardia A. Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-08 |
0.47 |
|
| 2020 |
Vidula N, Niemierko A, Malvarosa G, Brastianos P, Blouch E, Shannon K, Isakoff S, Wander S, Spring L, Younger J, Price K, Moy B, Juric D, Ellisen L, Bardia A. Abstract P4-09-06: Brain metastases (BM) in patients with metastatic breast cancer (MBC) and circulating cell-free DNA (cfDNA) somaticBRCAmutations Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-09-06 |
0.463 |
|
| 2020 |
Wander SA, Juric D, Spring LM, Vidula N, Beeler M, Habin K, Viscosi E, Scarpetti L, Tripp E, Hepp R, Moy B, Isakoff SJ, Ellisen LW, Bardia A. Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Ot2-08-01 |
0.426 |
|
| 2020 |
Cohen O, Mao P, Nayar U, Buendia-Bue JE, Kim D, Jain E, Helvie K, Abravanel D, Kowalski KJ, Kapstad C, Freeman S, Adalsteinsson V, Wander SA, Waks AG, Getz G, et al. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-02 |
0.468 |
|
| 2019 |
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, et al. FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31371343 DOI: 10.1158/1078-0432.Ccr-19-0138 |
0.432 |
|
| 2019 |
Wander SA, Spring LM, Bardia A. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. The Lancet. Oncology. PMID 31036469 DOI: 10.1016/S1470-2045(19)30279-7 |
0.364 |
|
| 2019 |
Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, Zhao D, Wander SA, Briegel K, Morey L, Minn A, Slingerland JM. p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. PMID 30877256 DOI: 10.1073/Pnas.1817415116 |
0.715 |
|
| 2019 |
Cornell L, Wander SA, Visal T, Wagle N, Shapiro GI. MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports. 26: 2667-2680.e7. PMID 30840889 DOI: 10.1016/J.Celrep.2019.02.023 |
0.488 |
|
| 2019 |
Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Current Oncology Reports. 21: 25. PMID 30806829 DOI: 10.1007/S11912-019-0769-3 |
0.437 |
|
| 2019 |
Waks AG, Cohen O, Kochupurakkal B, Kim D, Wander SA, Buendia-Buendia J, Helvie K, Matulonis UA, Krop IE, Tolaney SM, Winer EP, D'Andrea AD, Shapiro G, Lin NU, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1085-1085. DOI: 10.1200/Jco.2019.37.15_Suppl.1085 |
0.322 |
|
| 2019 |
Wander SA, Zangardi M, Niemierko A, Kambadakone A, Kim LS, Xi J, Pandey AK, Spring L, Stein C, Juric D, Kuter I, Moy B, Mulvey TM, Vidula N, Isakoff SJ, et al. A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1057-1057. DOI: 10.1200/Jco.2019.37.15_Suppl.1057 |
0.305 |
|
| 2019 |
Cohen O, Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock D, Leshchiner I, Dellostritto L, Garrido-Castro A, et al. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-02 |
0.359 |
|
| 2019 |
Wander S, Spring L, Stein C, Yuen M, Zangardi M, O'Shaughnessy J, Bardia A. Abstract P6-18-39: Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2- breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-18-39 |
0.439 |
|
| 2019 |
Mao P, Cohen O, Kowalski K, Kusiel J, Buendia J, Exman P, Wander SA, Waks AG, Winer EP, Lin NU, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-314 |
0.387 |
|
| 2018 |
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, et al. Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics. PMID 30531871 DOI: 10.1038/S41588-018-0287-5 |
0.39 |
|
| 2018 |
Mayer EL, Wander SA, Regan MM, DeMichele A, Forero-Torres A, Rimawi MF, Ma CX, Cristofanilli M, Anders CK, Bartlett CH, Winer EP, Burstein HJ. Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. Journal of Clinical Oncology. 36: TPS1104-TPS1104. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1104 |
0.388 |
|
| 2018 |
Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016 |
0.432 |
|
| 2018 |
Waks AG, Tolaney SM, Schnitt SJ, Dillon D, Gjini E, Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander SA, Stover DG, Rodig S, Krop IE, et al. The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal of Clinical Oncology. 36: 1054-1054. DOI: 10.1200/Jco.2018.36.15_Suppl.1054 |
0.383 |
|
| 2018 |
Picon-Ruiz M, Pan C, Drewes-Elger K, Jang K, Besser A, Zaho D, Morata-Tarifa C, Kim M, Ince T, Azzam D, Wander S, Cote R, Guy H, El-Ashry D, Torne-Poyatos P, et al. Abstract P6-05-01: Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/SOX2/miR-302b mediated malignant progression Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-05-01 |
0.772 |
|
| 2018 |
Mayer E, Wander S, Regan M, DeMichele A, Forero A, Rimawi M, Ma C, Cristofanilli M, Anders C, Bartlett CH, Koehler M, Winer E, Burstein H. Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-05-11 |
0.458 |
|
| 2018 |
Nayar U, Cohen O, Kapstad C, Waks A, Wander SA, Painter C, Freeman S, Ram P, Persky N, Marini L, Helvie K, Oliver N, Ma CX, Winer EP, Lin NU, et al. Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies Cancer Research. 78: 4952-4952. DOI: 10.1158/1538-7445.Am2018-4952 |
0.422 |
|
| 2017 |
Wander SA, Mayer EL, Burstein HJ. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017739482. PMID 28580881 DOI: 10.1200/Jco.2017.73.9482 |
0.355 |
|
| 2016 |
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. PMID 26993130 DOI: 10.1007/s10549-016-3752-9 |
0.557 |
|
| 2016 |
Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Research. PMID 26744520 DOI: 10.1158/0008-5472.Can-15-0927 |
0.782 |
|
| 2015 |
Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. PMID 25684140 DOI: 10.1038/Onc.2014.473 |
0.713 |
|
| 2014 |
Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Therapeutic Advances in Hematology. 5: 65-77. PMID 24883179 DOI: 10.1177/2040620714532123 |
0.318 |
|
| 2014 |
Zhao D, Besser AH, Zhou W, Wander SA, Sun J, Durante M, Hong F, Wang B, Ince T, Briegel K, Slingerland JM. Abstract 1145: Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor progression via Twist1 upregulation Cancer Research. 74: 1145-1145. DOI: 10.1158/1538-7445.Am2014-1145 |
0.74 |
|
| 2013 |
Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. Embo Molecular Medicine. 5: 1502-22. PMID 23982961 DOI: 10.1002/Emmm.201302558 |
0.759 |
|
| 2013 |
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. 138: 369-81. PMID 23430223 DOI: 10.1007/S10549-012-2389-6 |
0.726 |
|
| 2012 |
Azzam DJ, Elger KD, Zhao D, Ranganathan P, Capobianco T, Minn AJ, Creighton C, Picon M, Sun J, Pan C, Wander SA, Ashry DE, Slingerland JM. Abstract 3478: CD44+CD24low+progenitors in ER negative breast cancer have higher Notch1 activation, self-renewal, and chemo resistance and generate CD44+CD24negcells and tumors that metastasize Cancer Research. 72: 3478-3478. DOI: 10.1158/1538-7445.Am2012-3478 |
0.764 |
|
| 2012 |
Besser AH, Wander SA, Zhao D, Hong F, Wei JQ, Wang B, Ince T, Milikowski C, Nadji M, Briegel K, Bishopric N, Slingerland JM. Abstract 2224: Targeted PI3K/mTOR inhibition impairs tumor cell motility and bone metastatic outgrowth via modulation of p27 Cancer Research. 72: 2224-2224. DOI: 10.1158/1538-7445.Am2012-2224 |
0.712 |
|
| 2011 |
Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. The Journal of Clinical Investigation. 121: 1231-41. PMID 21490404 DOI: 10.1172/Jci44145 |
0.614 |
|
| 2011 |
Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 12-8. PMID 20966355 DOI: 10.1158/1078-0432.Ccr-10-0752 |
0.707 |
|
| 2011 |
Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment. 128: 69-78. PMID 20669046 DOI: 10.1007/S10549-010-1024-7 |
0.791 |
|
| 2011 |
Azzam DJ, Drews-Elger K, Zhao D, Chendong P, Wander SA, El-Ashry D, Slingerland JM. Abstract 3335: Self-renewal, tumorigenicity and metastatic potential of CD44+ cells in ER-negative lines and dissociated primary human breast cancers is increased in CD24+ subsets Cancer Research. 71: 3335-3335. DOI: 10.1158/1538-7445.Am2011-3335 |
0.762 |
|
| 2011 |
Wander SA, Zhao D, Hong F, Pan C, Chen Y, Jorda M, Slingerland JM. Abstract 2333: The atypical tumor suppressor p27 regulates cellular proliferation, invasion, and metastasis via subcellular localization in distinct microenvironments Cancer Research. 71: 2333-2333. DOI: 10.1158/1538-7445.Am2011-2333 |
0.716 |
|
| 2010 |
Wander SA, Hong F, Zhao D, Pan C, Larrea MD, Jorda M, Slingerland JM. Abstract 5137: The PI3K pathway regulates the actin cytoskeleton, tumor cell migration and metastasis via the atypical tumor suppressor p27 Cancer Research. 70: 5137-5137. DOI: 10.1158/1538-7445.Am10-5137 |
0.783 |
|
| 2009 |
Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle (Georgetown, Tex.). 8: 3455-61. PMID 19829074 DOI: 10.4161/Cc.8.21.9789 |
0.776 |
|
| 2009 |
Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America. 106: 9268-73. PMID 19470470 DOI: 10.1073/Pnas.0805057106 |
0.767 |
|
| Show low-probability matches. |